Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Matt Aaron Tschantz

Jin Mi Kim

Bryan Patrick McKibben

Neil Moss

Steven Richard Brunette

René Marc Lemieux

Hui Yu

Daniel R Goldberg

Hidenori Takahashi

Terence Alfred Kelly

Tina Marie Morwick

Mario G Cardozo

Roger John Snow

Abdelhakim Hammach

Usha R Patel

Michael Jason Burke

Xiao-Jun Wang

Anthony S Prokopowicz

Joerg Bentzien

Jennifer A Kowalski

Michael David Lawlor

Eugene R Hickey

Weimin Liu

Todd Bosanac

Rene Marc Lemieux

Derek Cogan

Zhaoming Xiong

Zhidong Chen

Donghong Amy Gao

Alexander Heim-Riether

Craig Andrew Miller

Wang Mao

Fariba Soleymanzadeh

Eric T Larson

Antonio J M Barbosa

Yue Shen

Joshua Courtney Horan

Yang Yu

Antonio Jose Del Moral Barbosa, Jr

Ryan Michael Fryer

Rene′ Marc Lemieux

Rene' Marc Lemieux

Eric Thomas Larson

Bryan Patrick Mckibben

Joerg Martin Bentzien

Bryan Mckibben

Donghong A Gao

Antonio Jose Del Moral Barbosa

The present invention encompasses compounds of the formula (I) wherein the groups R, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.

Heteroaromatic compounds as BTK inhibitors

The present invention encompasses compounds of the formulas (I) & (II), wherein the groups A, L and Ar are defined as in claim, which are suitable for the treatment of diseases related to KCa3.1, process of making, pharmaceutical preparations which contain compounds and their methods of use. 

Fused thiazin-3-ones as KCA3.1 inhibitors

Derivatives of 6,7-dihydro-5H-imidazo[1,2-&#x3b1;]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides

Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

[object Object]

Disclosed are novel compounds of formula (I): wherein X, Y, R, Rand Rare as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Pyrimidine derivatives useful as inhibitors of PKC-theta

The invention comprises a class of derivatives of substituted benzylimidazoles of the formula (I) and methods for making the same. These compounds are useful for the treatment of inflammatory conditions. 

Substituted benzylimidazoles useful for the treatment of inflammatory diseases

Disclosed are novel compounds of formula (I): wherein R, Rand Rare as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Pyridine derivatives useful as inhibitors of PKC-theta

Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

Derivatives of 6,7-dihydro-5H-imidazo[1,2-&#x3b1;]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide

Heterocyclic compounds useful as inhibitors of tyrosine kinases

Growing community of inventors

Newtown, CT, United States of America

Matt Aaron Tschantz